MedTrace Logo

The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil

NCT01024660 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2011-02-08

No results posted yet for this study

Summary

The purpose of this study is to determine if there is improvement or measurable change in cognition after only one month of treatment with donepezil when using a computerized test battery. The results at one month will be compared with the results at 3 months to evaluate this.

Conditions

Interventions

DRUG

Donepezil

5 mg capsule, orally, once daily, first 14 days of treatment

DRUG

Donepezil

10 mg, orally, once daily, for remaining 70 days of treatment

DRUG

Placebo to match Aricept

Placebo capsule, orally, 84 days of treatment

Sponsors & Collaborators

Principal Investigators

  • Malene Jensen · Study Delievery Director, AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Canada
  • Peru
  • Poland
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024660 on ClinicalTrials.gov